Peng Zhang1, Deng-Bo Ji1, Hai-Bo Han1, Yun-Fei Shi1, Chang-Zheng Du1, Jin Gu1. 1. Peng Zhang, Deng-Bo Ji, Chang-Zheng Du, Jin Gu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Colorectal Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, China.
Abstract
AIM: To investigate the correlation of miR-193a-5p with lymph node metastasis and postoperative survival of colorectal cancer (CRC) patients. METHODS: A total of 304 formalin-fixed, paraffin-embedded specimens (69 paired cancer and normal tissues, 55 primary tumors of stage III CRC and matched lymph nodes, and 56 primary tumors of stage II CRC) were included in this study. The relative expression levels of miR-193a-5p in the normal mucosa, primary cancer, and metastatic lymph node lesions were measured by quantitative real-time reverse transcriptase polymerase chain reaction. We evaluated the association of its expression with colorectal cancer lymph node metastasis, clinicopathological factors, and patient survival. RESULTS: The relative expression level of miR-193a-5p was significantly lower in CRC tissues than in the normal mucosa (P = 0.0060). The expression levels of miR-193a-5p were lower in primary CRC tissues with lymph node metastases than in those without metastases (P = 0.0006), and decreased expression of miR-193a-5p correlated with advanced lymph node metastatic stage (P = 0.0007). Kaplan-Meier analysis showed that patients with low miR-193a-5p expression had decreased disease-free survival (DFS) (P = 0.0026) and poor overall survival (OS) (P = 0.0003). Interestingly, for the group of patients with lymph node metastases, miR-193a-5p expression was also related to survival. Patients with low miR-193a-5p expression had decreased DFS (P = 0.0262) and poor OS (P = 0.0230). Moreover, multivariate analysis indicated that downregulation of miR-193a-5p was an independent predictor of poor OS. CONCLUSION: Downregulation of miR-193a-5p correlates with lymph node metastasis and poor survival of CRC. miR-193a-5p may be a useful biomarker for CRC diagnosis, metastasis and prognosis prediction.
AIM: To investigate the correlation of miR-193a-5p with lymph node metastasis and postoperative survival of colorectal cancer (CRC) patients. METHODS: A total of 304 formalin-fixed, paraffin-embedded specimens (69 paired cancer and normal tissues, 55 primary tumors of stage III CRC and matched lymph nodes, and 56 primary tumors of stage II CRC) were included in this study. The relative expression levels of miR-193a-5p in the normal mucosa, primary cancer, and metastatic lymph node lesions were measured by quantitative real-time reverse transcriptase polymerase chain reaction. We evaluated the association of its expression with colorectal cancer lymph node metastasis, clinicopathological factors, and patient survival. RESULTS: The relative expression level of miR-193a-5p was significantly lower in CRC tissues than in the normal mucosa (P = 0.0060). The expression levels of miR-193a-5p were lower in primary CRC tissues with lymph node metastases than in those without metastases (P = 0.0006), and decreased expression of miR-193a-5p correlated with advanced lymph node metastatic stage (P = 0.0007). Kaplan-Meier analysis showed that patients with low miR-193a-5p expression had decreased disease-free survival (DFS) (P = 0.0026) and poor overall survival (OS) (P = 0.0003). Interestingly, for the group of patients with lymph node metastases, miR-193a-5p expression was also related to survival. Patients with low miR-193a-5p expression had decreased DFS (P = 0.0262) and poor OS (P = 0.0230). Moreover, multivariate analysis indicated that downregulation of miR-193a-5p was an independent predictor of poor OS. CONCLUSION: Downregulation of miR-193a-5p correlates with lymph node metastasis and poor survival of CRC. miR-193a-5p may be a useful biomarker for CRC diagnosis, metastasis and prognosis prediction.
Authors: Agnieszka Bronisz; Yan Wang; Michal O Nowicki; Pierpaolo Peruzzi; Khairul Ansari; Daisuke Ogawa; Leonora Balaj; Gianluca De Rienzo; Marco Mineo; Ichiro Nakano; Michael C Ostrowski; Fred Hochberg; Ralph Weissleder; Sean E Lawler; E Antonio Chiocca; Jakub Godlewski Journal: Cancer Res Date: 2013-12-05 Impact factor: 12.701
Authors: T Yu; J Li; M Yan; L Liu; H Lin; F Zhao; L Sun; Y Zhang; Y Cui; F Zhang; J Li; X He; M Yao Journal: Oncogene Date: 2014-01-27 Impact factor: 9.867
Authors: Y Yang; L Zhou; L Lu; L Wang; X Li; P Jiang; L K Y Chan; T Zhang; J Yu; J Kwong; T H Cheung; T Chung; K Mak; H Sun; H Wang Journal: Oncogene Date: 2012-08-20 Impact factor: 9.867
Authors: N Zhang; X Li; C W Wu; Y Dong; M Cai; M T S Mok; H Wang; J Chen; S S M Ng; M Chen; J J Y Sung; J Yu Journal: Oncogene Date: 2012-12-03 Impact factor: 9.867
Authors: Stephen E Moss; John Greenwood; Xiaomeng Wang; Sabu Abraham; Jenny A G McKenzie; Natasha Jeffs; Matthew Swire; Vineeta B Tripathi; Ulrich F O Luhmann; Clemens A K Lange; Zhenhua Zhai; Helen M Arthur; James Bainbridge Journal: Nature Date: 2013-07-18 Impact factor: 49.962
Authors: Jane V Carter; Henry L Roberts; Jianmin Pan; Jonathan D Rice; James F Burton; Norman J Galbraith; Maurice R Eichenberger; Jeffery Jorden; Peter Deveaux; Russell Farmer; Anna Williford; Ziad Kanaan; Shesh N Rai; Susan Galandiuk Journal: Ann Surg Date: 2016-10 Impact factor: 12.969
Authors: Igor Lopes Dos Santos; Karlla Greick Batista Dias Penna; Megmar Aparecida Dos Santos Carneiro; Larisse Silva Dalla Libera; Jéssica Enocencio Porto Ramos; Vera Aparecida Saddi Journal: Mol Biol Rep Date: 2021-02-17 Impact factor: 2.316